This was the stock's second consecutive day of losses.
GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.
Nearly all of Latin America was excluded from the deal, sparking concern the world is missing a critical opportunity to stop ...
Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...
2hon MSN
Ballard Partners, whose founder has personal ties to Donald Trump, seems poised to profit from Trump's return to Washington, ...
Jason Eckelberry jumped in a lake to rescue a boy in Morrow County Tuesday. Xavior Sexton, 12, is doing fine, his mother said ...
Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...
Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...
During the 2023/24 fiscal year TIC registered an impressive 707 investment projects spanning key sectors, including ...
Serious outcomes associated with metabolic dysfunction-associated steatotic liver disease (MASLD) -- including liver cancer, ...
14hon MSNOpinion
We face a crucial decision as President-elect TrumpÂ’s team takes shape and begins to govern: whether to view other Americans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback